Short answer
ROCKET PHARMACEUTICALS, INC. (RCKT) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial information announced for quarter ended September 30, 2026.
ROCKET PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial information announced for quarter ended September 30, 2026
- Investor focus: Exhibit 99.1 contains the company’s detailed results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- FDA alignment supports a 12-patient RP-A501 pivotal Phase 2, with dosing targeted by mid-2027 and topline results in mid-2028
- Danon efficacy bar: at least 7 of 12 patients meeting both LAMP2 expression and 10% LV mass-index reduction endpoints
- KRESLADI commercial readiness reached October 1, 2026, with 2 Qualified Treatment Centers ready for patient onboarding
- Cash $279.4M, including the initial $35M Hercules draw, expected to fund operations into Q3 2028
- Q3 net loss $49.2M, or $0.43 per share, versus $50.3M, or $0.45, in Q3 2025
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ROCKET PHARMACEUTICALS, INC. 8-K filings
Get the next RCKT 8-K as it lands
Follow RCKT for push alerts, or ask the research agent what this filing means.